KKR to invest about $150 mln in India's Gland Pharma-sources
MUMBAI Oct 11 (Reuters) - U.S. private equity firm KKR & Co LP will pay about $150 million for close to 30 percent of India's Gland Pharma Ltd, two sources with direct knowledge of the matter told Reuters.
A deal is likely to be announced in the coming weeks, one of the sources said on Friday.
KKR India Chief Executive Sanjay Nayar declined to comment, while Gland Pharma Vice Chairman Ravi Penmetsa was not immediately available for comment.
The deal would be KKR's second sizeable India investment in six months. In April, it bought a controlling stake in India's Alliance Tire Group from Warburg Pincus LLC for what sources said was about $500 million.
Established in 1978, unlisted Gland Pharma makes active pharmaceutical ingredients and injectable formulations for segments including osteoarthritis, anti-coagulants, gynaecology, and ophthalmology, according to its website.
Private equity investments in India fell about 67 percent in the September quarter from a year earlier, to about $1.3 billion in 75 deals, according to early data from Venture Intelligence.
- Malaysia Airlines plane missing at sea off Vietnam, presumed crashed |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Malaysian plane crashed off Vietnam coast: state media
- Fresh confrontations raise tempers on ground in Crimea |